---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-029687"
form_type: "8-K"
ticker: "TRAW"
cik: "0001130598"
company_name: "Traws Pharma, Inc."
filed_at: "2025-03-31T23:59:59+00:00"
generated_at: "2026-05-24T01:30:18.807718+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Traws Pharma reports FY2024 net loss of $166.5M; CEO Werner Cautreels retiring, Iain D. Dukes Interim CEO

## Summary
- Net loss of $166.5M ($35.21/share) for FY2024, driven by $117.5M acquired IPR&D and $24.4M warrant expense.
- Cash, cash equivalents and short-term investments $21.3M as of Dec 31, 2024; cash runway into Q1 2026.
- CEO Werner Cautreels retiring as of March 31, 2025; Interim CEO Iain D. Dukes appointed, continuing as Chairman.
- Lead candidate tivoxavir marboxil shows positive efficacy in three animal models for H5N1 bird flu; Phase 1 complete; FDA interaction sought under Animal Rule.
- R&D expense $12.8M (up $1.4M); G&A expense $12.3M (up $3.2M) for FY2024.

## SEC filing metadata
- accession: 0001104659-25-029687
- form_type: 8-K
- ticker: TRAW
- cik: 0001130598
- company_name: Traws Pharma, Inc.
- filed_at: 2025-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1130598/000110465925029687/0001104659-25-029687-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1130598/000110465925029687/tm2510891d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-029687
- JSON: https://secwatch.observer/filing/0001104659-25-029687.json
- Plain text: https://secwatch.observer/filing/0001104659-25-029687.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.